Aytu BioPharma Transfers Rights To AR101 Back To EnzCo, Ending Development And Terminating Rumpus Agreement With No Further Obligations

Author: Benzinga Newsdesk | August 07, 2025 05:51pm

As previously disclosed in its United States Securities and Exchange Commission filings, Aytu BioPharma, Inc. (the "Company") suspended its clinical development of AR101. In connection with this suspension, the Company has been engaged in negotiations with EnzCo, LLC ("EnzCo") and Rumpus VEDS LLC, ("Rumpus VEDS"), Rumpus Therapeutics LLC, ("Rumpus Therapeutics") and Rumpus Vascular LLC, ("Rumpus Vascular" and, together with Rumpus VEDS and Rumpus Therapeutics, "Rumpus") for the repurchase of AR101. On August 5, 2025, the Company, Rumpus and EnzCo reached terms whereby for mutual consideration and releases, the Company transferred all of its and Rumpus' rights, title and interest in AR101 to EnzCo, which extinguished and terminated all obligations of the Company and Rumpus under the April 21, 2021 asset purchase agreement by and between the Company and Rumpus (the "Asset Purchase Agreement"). There is no other relationship between the Company, EnzCo or Rumpus other than as contracting parties to terminate the Asset Purchase Agreement, and there are no penalties or remaining obligations to the Company for terminating the Asset Purchase Agreement.

Posted In: AYTU